MGMT gene silencing and benefit from temozolomide in glioblastoma.

MLA

Hegi ME, et al. “MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma.” New England Journal of Medicine, vol. 352, no. 10, Mar. 2005, pp. 997–1003. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=asx&AN=106475148&authtype=sso&custid=ns315887.

APA

Hegi ME, Diserens A, Gorlia T, Hamou M, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JEC, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R, Hegi, M. E., Diserens, A.-C., Gorlia, T., & Hamou, M.-F. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. New England Journal of Medicine, 352(10), 997–1003.

Chicago

Hegi ME, Diserens A, Gorlia T, Hamou M, de Tribolet N, Weller M, Kros JM, et al. 2005. “MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma.” New England Journal of Medicine 352 (10): 997–1003. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=asx&AN=106475148&authtype=sso&custid=ns315887.